Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study.

IF 4.1 2区医学 Q2 NUTRITION & DIETETICS

Nutrition & Metabolism Pub Date : 2025-07-17 DOI:10.1186/s12986-025-00969-2

Xiaoya Wang, Zefeng Xing, Rui Wang, Guoming Zhang, Guodong Liu, Zhen Li, Lixiang Li

{"title":"Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study.","authors":"Xiaoya Wang, Zefeng Xing, Rui Wang, Guoming Zhang, Guodong Liu, Zhen Li, Lixiang Li","doi":"10.1186/s12986-025-00969-2","DOIUrl":null,"url":null,"abstract":"Background: Bifidobacterium longum subsp. longum BL21 has demonstrated promise in alleviating gut microbiota disturbances and metabolic regulation in high-fat diet-induced obesity and type 2 diabetes mellitus models. However, the effect of probiotic B. longum BL21 on overweight and obese individuals remain unclear.Methods: A randomized, double-blind, placebo-controlled trial was performed, and 66 adult individuals were assigned to receive either BL 21 (2*1010 colony-forming units per day along with 3 g of maltodextrin) or placebo (3 g of maltodextrin daily) for 8 weeks. Multi-omics analyses were employed to evaluate the impact of the B. longum strain BL21 on gut microbiota, serum metabolomics, body weight and lipids profiles in overweight and obese participants.Results: Following the intervention, both the BL21 group (1.22 ± 2.78, P = 0.02) and placebo group (0.98 ± 2.06, P = 0.01) demonstrated significant body weight reductions, with no statistically significant intergroup difference observed (P = 0.81). Notably, only the BL21 group exhibited a significant reduction in triglyceride levels compared to baseline (0.21 ± 1.09, P = 0.04). Microbiota analysis indicated that BL21 intervention significantly changed the β-diversity at week 8 compared with placebo group. The genera of Parasutterella, Parabacteroides, Blautia, Dorea, Butyricicoccus enriched in BL21 group. Metabolomics results indicated that sphingolipid metabolism, biotin metabolism and protein digestion and absorption were the top altered pathway in BL21 group compared with placebo group after intervention.Conclusion: B. longum subsp. longum BL21 may be a beneficial candidate to modulate the gut microbiota and triglyceride metabolism of overweight and obese individuals.Trial registration: Clinical trial registration number: NCT06140641. Date of registration: November 17, 2023.","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":"22 1","pages":"79"},"PeriodicalIF":4.1000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273011/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12986-025-00969-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Bifidobacterium longum subsp. longum BL21 has demonstrated promise in alleviating gut microbiota disturbances and metabolic regulation in high-fat diet-induced obesity and type 2 diabetes mellitus models. However, the effect of probiotic B. longum BL21 on overweight and obese individuals remain unclear.

Methods: A randomized, double-blind, placebo-controlled trial was performed, and 66 adult individuals were assigned to receive either BL 21 (2*10¹⁰ colony-forming units per day along with 3 g of maltodextrin) or placebo (3 g of maltodextrin daily) for 8 weeks. Multi-omics analyses were employed to evaluate the impact of the B. longum strain BL21 on gut microbiota, serum metabolomics, body weight and lipids profiles in overweight and obese participants.

Results: Following the intervention, both the BL21 group (1.22 ± 2.78, P = 0.02) and placebo group (0.98 ± 2.06, P = 0.01) demonstrated significant body weight reductions, with no statistically significant intergroup difference observed (P = 0.81). Notably, only the BL21 group exhibited a significant reduction in triglyceride levels compared to baseline (0.21 ± 1.09, P = 0.04). Microbiota analysis indicated that BL21 intervention significantly changed the β-diversity at week 8 compared with placebo group. The genera of Parasutterella, Parabacteroides, Blautia, Dorea, Butyricicoccus enriched in BL21 group. Metabolomics results indicated that sphingolipid metabolism, biotin metabolism and protein digestion and absorption were the top altered pathway in BL21 group compared with placebo group after intervention.

Conclusion: B. longum subsp. longum BL21 may be a beneficial candidate to modulate the gut microbiota and triglyceride metabolism of overweight and obese individuals.

Trial registration: Clinical trial registration number: NCT06140641. Date of registration: November 17, 2023.

查看原文本刊更多论文

多组学分析了长双歧杆菌亚种的作用。对超重和肥胖受试者补充longum BL21：一项随机、双盲、安慰剂对照研究。

背景：长双歧杆菌亚种。longum BL21在高脂肪饮食引起的肥胖和2型糖尿病模型中显示出缓解肠道微生物群紊乱和代谢调节的希望。然而，益生菌长芽孢杆菌BL21对超重和肥胖个体的影响尚不清楚。方法：进行了一项随机、双盲、安慰剂对照试验，66名成年人被分配接受BL 21（每天2*1010个菌落形成单位，同时服用3g麦芽糊精）或安慰剂（每天服用3g麦芽糊精），为期8周。采用多组学分析来评估长芽孢杆菌菌株BL21对超重和肥胖参与者肠道微生物群、血清代谢组学、体重和脂质谱的影响。结果：干预后，BL21组（1.22±2.78,P = 0.02）和安慰剂组（0.98±2.06,P = 0.01）的体重均有显著下降，组间差异无统计学意义（P = 0.81）。值得注意的是，与基线相比，只有BL21组甘油三酯水平显著降低（0.21±1.09,P = 0.04）。微生物群分析表明，与安慰剂组相比，BL21干预在第8周显著改变了β-多样性。在BL21组中，Parasutterella、Parabacteroides、Blautia、Dorea、Butyricicoccus等属富集。代谢组学结果显示，干预后，与安慰剂组相比，BL21组鞘脂代谢、生物素代谢和蛋白质消化吸收是改变最大的途径。结论：长芽孢杆菌；longum BL21可能是调节超重和肥胖个体肠道微生物群和甘油三酯代谢的有益候选物。试验注册：临床试验注册号：NCT06140641。报名日期：2023年11月17日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition & Metabolism 医学-营养学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Nutrition & Metabolism publishes studies with a clear focus on nutrition and metabolism with applications ranging from nutrition needs, exercise physiology, clinical and population studies, as well as the underlying mechanisms in these aspects. The areas of interest for Nutrition & Metabolism encompass studies in molecular nutrition in the context of obesity, diabetes, lipedemias, metabolic syndrome and exercise physiology. Manuscripts related to molecular, cellular and human metabolism, nutrient sensing and nutrient–gene interactions are also in interest, as are submissions that have employed new and innovative strategies like metabolomics/lipidomics or other omic-based biomarkers to predict nutritional status and metabolic diseases. Key areas we wish to encourage submissions from include: -how diet and specific nutrients interact with genes, proteins or metabolites to influence metabolic phenotypes and disease outcomes; -the role of epigenetic factors and the microbiome in the pathogenesis of metabolic diseases and their influence on metabolic responses to diet and food components; -how diet and other environmental factors affect epigenetics and microbiota; the extent to which genetic and nongenetic factors modify personal metabolic responses to diet and food compositions and the mechanisms involved; -how specific biologic networks and nutrient sensing mechanisms attribute to metabolic variability.